<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Genomic Health Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/genomic-health-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(GHDX) Genomic Health to Showcase Key Data</title>
		<link>http://www.stockbloghub.com/2011/12/01/ghdx-genomic-health-to-showcase-key-data/87809</link>
		<comments>http://www.stockbloghub.com/2011/12/01/ghdx-genomic-health-to-showcase-key-data/87809#comments</comments>
		<pubDate>Thu, 01 Dec 2011 15:13:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>
		<category><![CDATA[Natural Gas Services Group Inc]]></category>
		<category><![CDATA[NGS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87809</guid>
		<description><![CDATA[Genomic Health (GHDX), an oncology based biotech company, will present results from 16 studies at the San Antonio Breast Cancer Symposium in December. The company has been recording robust revenue growth over the last few quarters banking on its flagship product, Oncotype DX breast cancer test. The test is used for early stage breast cancer patients to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit. Although the Oncotype DX colon cancer test was launched in 2010, it is yet to make a significant contribution to the top line. Genomic Health has undertaken several studies to expand the use of Oncotype DX. The company is studying the utility of the Oncotype DX test in patients with ductal carcinoma in situ (DCIS). Preliminary results ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/ghdx-genomic-health-to-showcase-key-data/87809/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Heath Incorporated &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/07/23/ghdx-genomic-heath-incorporated-bear-of-the-day/44372</link>
		<comments>http://www.stockbloghub.com/2010/07/23/ghdx-genomic-heath-incorporated-bear-of-the-day/44372#comments</comments>
		<pubDate>Fri, 23 Jul 2010 15:09:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44372</guid>
		<description><![CDATA[Genomic Health&#8217;s (GHDX) first quarter 2010 loss of $0.07 per share missed the Zacks Consensus Estimate of a loss of $0.03. Although the company&#8217;s lead product, Oncotype DX breast cancer test, recorded a year-over-year growth of 20%, revenues declined sequentially. Meanwhile, Genomic launched its colon cancer test in January 2010, though this test will take a fair amount of time before contributing significantly to the top line. As a result, the company is solely dependent on the breast cancer test. Moreover, we are concerned about the outcome of the FDA meeting on LDTs, the outcome of which might have a long-term impact on the company. Other pipeline tests at Genomic have a long way to go before commercialization, as well. Given these factors, we downgrade the stock to Underperform. We ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/23/ghdx-genomic-heath-incorporated-bear-of-the-day/44372/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health&#8217;s Loss Wider Than Expected</title>
		<link>http://www.stockbloghub.com/2010/05/06/ghdx-genomic-healths-loss-wider-than-expected/36425</link>
		<comments>http://www.stockbloghub.com/2010/05/06/ghdx-genomic-healths-loss-wider-than-expected/36425#comments</comments>
		<pubDate>Thu, 06 May 2010 20:31:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36425</guid>
		<description><![CDATA[Genomic Health Inc’s (GHDX) first quarter 2010 loss of 7 cents per share was wider than the Zacks Consensus Estimate of a net loss of 3 cents. The company had suffered a loss of 16 cents in the prior-year period. Total revenues for the reported quarter came in at $41.2 million as against $33.9 million in the year-ago quarter, up 21.5% year over year. Product revenues from the Oncotype DX breast cancer test climbed approximately 20% year over year to $40.3 million in the first quarter of 2010. Contract revenues accounted for the balance. In the first quarter of 2010, Genomic Health delivered in excess of 13,310 test results, as against more than 11,210 test results in the comparable period of 2009, representing approximately a 19% year-over-year growth. Research and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/06/ghdx-genomic-healths-loss-wider-than-expected/36425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DGX) Why Healthcare Reform Should Help The Diagnostics Industry</title>
		<link>http://www.stockbloghub.com/2010/04/01/dgx-why-healthcare-reform-should-help-the-diagnostics-industry/32633</link>
		<comments>http://www.stockbloghub.com/2010/04/01/dgx-why-healthcare-reform-should-help-the-diagnostics-industry/32633#comments</comments>
		<pubDate>Thu, 01 Apr 2010 21:37:50 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Bio-Reference Laboratories Inc]]></category>
		<category><![CDATA[BRLI]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[Genoptix]]></category>
		<category><![CDATA[GHDX]]></category>
		<category><![CDATA[GXDX]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32633</guid>
		<description><![CDATA[America seems to be divided into two camps… Not blue states versus red states. Not Yankees fans versus Red Sox fans (although why you’d be the latter I’ll never understand). Not even people who support the new healthcare reform bill versus those who are opposed to it. Rather, I’m talking about the difference between people who run to the doctor for every little ache and pain, compared with those who wouldn’t go within 50 yards of a doctor’s office even if their internal organs suddenly became external… The Diagnostics Industry: More Healthcare Coverage Means More Business My family and I try to stay out of doctor’s offices. This has been the case, ever since a routine visit to get my six-year-old son some orthopedics in his shoes turned into scheduled ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/dgx-why-healthcare-reform-should-help-the-diagnostics-industry/32633/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health Announces New Distribution Deal</title>
		<link>http://www.stockbloghub.com/2010/03/29/ghdx-genomic-health-announces-new-distribution-deal/32185</link>
		<comments>http://www.stockbloghub.com/2010/03/29/ghdx-genomic-health-announces-new-distribution-deal/32185#comments</comments>
		<pubDate>Mon, 29 Mar 2010 20:52:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32185</guid>
		<description><![CDATA[Recently, Genomic Health, Inc. (GHDX) announced that it has agreed to distribute its breast cancer assay Oncotype DX with Palex Medical S.A. in Spain and Portugal. The company also announced encouraging data on Oncotype DX at the 7th European Breast Cancer Conference in Barcelona. The deal with Palex Medical, a leading player in the distribution of medical devices in Spain and Portugal, further expands the international presence of Genomic Health’s lead product. The transaction aims to provide physicians and patients with increased access to this advanced diagnostic test in the European market. As of December 2009, more than 8,000 physicians had ordered in excess of 135,000 Oncotype DX tests in over 55 countries. In addition to the agreement, Genomic Health announced data from two studies which further underline the benefits ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/ghdx-genomic-health-announces-new-distribution-deal/32185/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health Announces Commercial Availability Of Its Oncotype DX Colon Cancer Test</title>
		<link>http://www.stockbloghub.com/2010/01/23/ghdx-genomic-health-announces-commercial-availability-of-its-oncotype-dx-colon-cancer-test/25804</link>
		<comments>http://www.stockbloghub.com/2010/01/23/ghdx-genomic-health-announces-commercial-availability-of-its-oncotype-dx-colon-cancer-test/25804#comments</comments>
		<pubDate>Sat, 23 Jan 2010 21:18:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25804</guid>
		<description><![CDATA[Recently, Genomic Health, Inc. (GHDX) announced the global commercial availability of its Oncotype DX colon cancer test. The 12-gene diagnostic test aims to predict individual recurrence risk in stage II colon cancer patients after surgery. The Genomic Health test is the first multigene expression test developed for assessing the risk of recurrence in patients suffering from stage II colon cancer. Stage II colon cancer (also known as Dukes&#8217; Stage B) affects approximately 30,000 -40,000 people annually in the United States and the current treatment paradigm is not very clear. About a third of the patients receive chemotherapy post surgery. However, research indicates that chemotherapy benefits only 2% to 4% of patients. Furthermore, the treatment has significant associated toxicity. The decision to treat patients with chemotherapy post surgery is based on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/23/ghdx-genomic-health-announces-commercial-availability-of-its-oncotype-dx-colon-cancer-test/25804/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health Provides Revenue Guidance</title>
		<link>http://www.stockbloghub.com/2010/01/08/ghdx-genomic-health-provides-revenue-guidance/24502</link>
		<comments>http://www.stockbloghub.com/2010/01/08/ghdx-genomic-health-provides-revenue-guidance/24502#comments</comments>
		<pubDate>Fri, 08 Jan 2010 21:01:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24502</guid>
		<description><![CDATA[Genomic Health, Inc. (GHDX) announced recently that it is confident of meeting the annual revenue guidance for the fiscal year 2009, ended Dec 31. The company expects to report revenues of $149.5 million for fiscal 2009. This represents a 35% increase on revenues of $110.6 million reported by Genomic Health in fiscal 2008. Genomic Health further announced that it expects to report revenues of $39.5 million in the fourth quarter of fiscal 2009. This represents a 26% increase on revenues of $31.2 million reported by the company in the fourth quarter of 2008. However the preliminary revenues for the quarter would be affected adversely by payment delays of approximately $2.5 million, from Anthem Insurance Companies and the Blue Card program administered by Blue Shield of California. Genomic Health expects to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/08/ghdx-genomic-health-provides-revenue-guidance/24502/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health, Inc Reveals Oncotype DX Data</title>
		<link>http://www.stockbloghub.com/2009/12/11/ghdx-genomic-health-inc-reveals-oncotype-dx-data/22634</link>
		<comments>http://www.stockbloghub.com/2009/12/11/ghdx-genomic-health-inc-reveals-oncotype-dx-data/22634#comments</comments>
		<pubDate>Fri, 11 Dec 2009 22:48:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22634</guid>
		<description><![CDATA[Genomic Health, Inc. (GHDX) announced that positive results were published in the journal, The Lancet Oncology, from a study of the company’s growth engine, Oncotype DX, in postmenopausal women suffering from node-positive, estrogen receptor-positive breast cancer. The study was conducted by the Southwest Oncology Group (SWOG) and funded by the National Cancer Institute and Genomic Health. The findings were presented at the American Association for Cancer Research San Antonio Breast Cancer Symposium. The study evaluated whether the Oncotype DX test can predict, which women would stand to gain from chemotherapy. The study not only evaluated the efficacy of 21 genes from a tumor but also produced a score that predicts chemotherapy benefit. The analysis suggested that women having a low score on the Oncotype DX test did not appear to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/ghdx-genomic-health-inc-reveals-oncotype-dx-data/22634/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health Third Quarter Loss Narrows</title>
		<link>http://www.stockbloghub.com/2009/11/08/ghdx-genomic-health-third-quarter-loss-narrows/19881</link>
		<comments>http://www.stockbloghub.com/2009/11/08/ghdx-genomic-health-third-quarter-loss-narrows/19881#comments</comments>
		<pubDate>Mon, 09 Nov 2009 02:46:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19881</guid>
		<description><![CDATA[Genomic Health Inc. (GHDX) suffered a third quarter loss of 2 cents per share, which was better than the Zacks Consensus Estimate of a loss of 9 cents. The company suffered a loss of 11 cents in the prior-year period. Total revenues for the quarter came in at $39.5 million, compared with $28.1 million in the third quarter of 2008, up 40.6%. Product revenues from the Oncotype DX breast cancer test increased 39% to $38.9 million, compared with $28.1 million in the comparable quarter of 2008. Contract revenues accounted for the balance. In the third quarter, Genomic Health delivered in excess of 12,600 test results, compared with more than 10,220 test results in the comparable period of 2008, representing approximately a 23% year-over-year growth. Research and development spend for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/08/ghdx-genomic-health-third-quarter-loss-narrows/19881/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Genomic Health&#8217;s Results Reveal Oncotype DX Utility</title>
		<link>http://www.stockbloghub.com/2009/10/14/ghdx-genomic-healths-results-reveal-oncotype-dx-utility/17568</link>
		<comments>http://www.stockbloghub.com/2009/10/14/ghdx-genomic-healths-results-reveal-oncotype-dx-utility/17568#comments</comments>
		<pubDate>Wed, 14 Oct 2009 16:28:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Clarient Inc]]></category>
		<category><![CDATA[CLRT]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17568</guid>
		<description><![CDATA[Recently, Genomic Health Inc. (GHDX) announced data which confirmed that manual micro dissection (dissection of tissue or cells under the microscope) of biopsy cavities is essential for the accurate assessment of recurrence risk in patients with early-stage breast cancer. Genomic Health&#8217;s Oncotype DX is the only commercially available breast cancer test that makes use of manual microdissection following review by a board certified surgical pathologist with expertise in breast cancer to predict a patient&#8217;s benefit from chemotherapy and risk of disease recurrence. The results from the study revealed that the inclusion of biopsy cavities in breast cancer specimens is associated with significant changes in the expression of individual genes. Consequently, it was found that biopsy cavities had high-risk Recurrence Scores. Genomic also presented results which demonstrated ability of Oncotype DX ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/14/ghdx-genomic-healths-results-reveal-oncotype-dx-utility/17568/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GHDX) Good News for Genomic Health</title>
		<link>http://www.stockbloghub.com/2009/09/04/ghdx-good-news-for-genomic-health/14460</link>
		<comments>http://www.stockbloghub.com/2009/09/04/ghdx-good-news-for-genomic-health/14460#comments</comments>
		<pubDate>Fri, 04 Sep 2009 23:17:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[Genomic Health Inc.]]></category>
		<category><![CDATA[GHDX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14460</guid>
		<description><![CDATA[Yesterday, Genomic Health, Inc. (GHDX) announced that a number of leading U.S. surgeons ask for Genomic Health&#8217;s Oncotype DX breast cancer assay at the time of surgery or biopsy, in an effort to provide patients with prompt, critical information about treatment options available at their maiden visit to an oncologist. Oncotype DX, the growth engine of the company, was launched in 2004. It is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In late May 2009, Genomic Health announced that more than 100,000 test results have been delivered in over 40 countries worldwide since the commercial launch of Oncotype DX. The assay analyzes the activity of 21 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/ghdx-good-news-for-genomic-health/14460/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

